Introduction Phosphodiesterase type 5 inhibitors (PDE5Is) have demonstrated efficacy in the
treatment of erectile dysfunction (ED). Although historically found to have limited drug …

Abstract PDE5 inhibitors (PDE5i) are widely known as treatment for erectile dysfunction
(ED). This favorable action has emerged as a “side effect” from pioneering studies when …

The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly
understood following the pioneering work with sildenafil, and the continuing development …

Oral phosphodiesterase type 5 (PDE5) inhibitors remain the standard pharmacologic
treatment for erectile dysfunction (ED). ED, a pervasive disorder that is common in men older …

Phosphodiesterase-5 inhibitors (PDE5i, sildenafil, vardenafil, tadalafil and avanafil) are a
first-line medical therapy for erectile dysfunction (ED). In all likelihood, PDE5i usage will …

Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral
pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of …

The introduction of oral agents for the treatment of erectile dysfunction (ED) has
revolutionized the treatment of men with erection problems of all severities and etiologies …

Ethnopharmacological relevance The prevalence and distress caused by erectile
dysfunction (ED) to both male and female partners are increasing at a steady rate. ED has …

Introduction In recent years, PDE5 inhibitors (PDE5i) use has become more popular among
men without ED to enhance sexual performance. However, reports in the literature are …

PDE5 belongs to a superfamily of enzymes that catalyzes the hydrolysis of cyclic nucleotides
cAMP and cGMP to the corresponding 5-nucleoside monophosphate. PDE5 takes part in …